Allergan Beats, Revisits Guidance - Analyst Blog
August 03 2011 - 10:47AM
Zacks
Allergan, Inc.’s (AGN) second quarter 2011
earnings of 96 cents per share inched ahead of the Zacks Consensus
Estimate by a penny and surpassed the company’s guidance range of
93 – 95 cents. Earnings increased 12.9% from the year-ago
quarter.
Revenues
Revenues increased 13.6% to $1,417.2 million, easily exceeding
the Zacks Consensus Estimate of $1,339 million.
Specialty pharmaceuticals sales increased 14.0% to $1,155.3
million, with eye care pharmaceutical sales increasing 13.8%.
Strong performance of products like Lumigan and Restasis helped
drive eye-care sales.
Alphagan and Combigan franchise sales went up 4.1% to $108.5
million in the reported quarter. New product Latisse contributed
$21.9 million to the second quarter sales.
Botox sales increased 16.1% year on year to $418.4 million.
Going forward, Allergan is looking to boost Botox sales by gaining
approval for additional indications.
Meanwhile, Allergan’s medical devices segment also delivered
growth, with sales increasing 12.2% to $245.1 million. While breast
aesthetics sales increased 17.0% to $95.5 million, facial filler
sales shot up 26.9% to $95.2 million.
However, obesity intervention sales continued to disappoint with
sales declining 12.1% to $54.4 million. The medical devices segment
faces competition from companies like Johnson &
Johnson (JNJ) and Medicis Pharmaceutical
Corp. (MRX).
Other Details
Selling, general and administrative (SG&A) expenses went up
13.9% during the quarter to $563.2 million, while research and
development (R&D) expenses amounted to $212.4 million,
reflecting an upside of 13.2%.
Allergan declared a quarterly dividend of 5 cents per share for
the second quarter.
Pipeline Update
During the second quarter, Allergan submitted a New Drug
Application (NDA) to the US Food and Drug Administration (FDA) for
Levadex to be used as a treatment of migraine in adults. The
company had entered into an agreement with MAP
Pharmaceuticals, Inc. (MAPP) in January for the marketing
of Levadex in the US.
In June, the European Medicines Agency (EMA) approved the use of
Ozurdex as a treatment for inflammation of the posterior segment of
the eye presenting as non-infectious uveitis. The drug is already
marketed in the European Union (EU) for the treatment of macular
edema associated with retinal vein occlusion. Moreover, Ozurdex is
available in the US for both the indications.
We would like to remind investors that Allergan is seeking
approval for the use of Botox for the treatment of urinary
continence. The company has already filed the supplemental
Biologics License Application (sBLA) for the said indication and
expects to gain approval by the end of 2011.
2011 Guidance Revised
Allergan increased it 2011 earnings guidance to a range of $3.59
- $3.63 per share from a range of $3.56 - $3.62. The Zacks
Consensus Estimate of $3.64 lies above the company’s guidance
range. Allergan expects product net sales to range from $5,220 -
$5,370 million (previous guidance: $5,050 - $5,250 million).
For 2011, Allergan expects total specialty pharmaceuticals net
sales in the range of $4,310 - $4,440 million (previous guidance:
$4,170 - $4,310 million). Sales is expected to be driven by Botox
(guidance: $1,550 - $1,590 million; revised from $1,500 - $1,550
million).
Medical devices net sales are expected in the range of $910 -
$930 million (previous guidance: $880 - $940 million) in 2011.
Here, performance will be driven mainly by facial aesthetics
(guidance: $360 - $370 million; revised from $330 - $350 million).
The US approval of Juvederm XC, Allergan’s latest facial filler
product, should help drive facial aesthetics sales.
Allergan also provided guidance for the third quarter of 2011.
The company expects to earn 88 - 90 cents on total product net
sales of $1,265 - $1,340 million. The Zacks Consensus Estimate lies
within the guidance range at 91 cents.
Neutral on Allergan
We currently have a Neutral recommendation on Allergan. The
stock carries a Zacks #3 Rank (Hold rating) in the short-run.
Although the company is facing significant challenges due to the
global economic weakness, European pricing pressure, US healthcare
reform, safety issues surrounding the use of Botox, and increased
competition, we think Allergan will be able to counter these
challenges and will be back on its historical earnings growth
trajectory.
ALLERGAN INC (AGN): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
MAP PHARMACEUT (MAPP): Free Stock Analysis Report
MEDICIS PHARM-A (MRX): Free Stock Analysis Report
Zacks Investment Research
Map Pharmaceuticals, Inc. (MM) (NASDAQ:MAPP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Map Pharmaceuticals, Inc. (MM) (NASDAQ:MAPP)
Historical Stock Chart
From Jul 2023 to Jul 2024